Victor Hugo Schaly Cordova
Psychiatry Schizophrenia research and treatment Treatment of Major Depression Pharmacology Psychiatry and Mental health

Bio

Victor Hugo Schaly Cordova is a dedicated researcher and academic based in Porto Alegre, Brazil. He is affiliated with the Federal University of Rio Grande do Sul (UFRGS), where he contributes to the field of psychiatry and behavioral science. With a background as a Biologist, Pharmacist, and Master in Psychiatry and Behaviour Science, his work focuses on the intersection of psychotropic drugs, therapeutic management, and inflammatory markers in psychiatric conditions. He has authored papers such as 'The link between Social Anxiety and Peripheral Inflammatory Markers in patients with Schizophrenia diagnoses' and 'Psychotropic Drugs and Covid-19 Therapeutic Management'. Victor Hugo has an active research profile with 21 publications, 37 citations, an h-index of 4, and an i10-index of 1. He also serves as a reviewer for the Global Journal of Medical Research (GJMR) and maintains an ORCID iD of 0000-0001-6147-1250.

Educational Journey

Universidade do Extremo Sul Catarinense

BACHAREL

2013

Federal University of Rio Grande do Sul

Biologist, Pharmacist and Master in Psychiatry and Behaviour Science.

Universidade Federal do Rio Grande do Sul - Faculdade de Farmácia

Experience

Hospital de Clínicas de Porto Alegre

2016 - Present • SERVIÇO DE PSIQUIATRIA

0 - 0

Universidade do Extremo Sul Catarinense

0 - 0

Editors Role

Reviewer

GJMR

2024 - Present

Research

The link between Social Anxiety and Peripheral Inflammatory Markers in patients with Schizophrenia diagnoses

Article January 23, 2026

Background: It exist increasing studies on the inflammatory process in psychiatric disorders, in which inflammation in schizophrenia (SZ) isquestioned. Objective: assess the association between social anxiety (SA) and inflammation in patients with SZ, measuring primarily the neutrophil-to-lymphocyte ratio (NLR) and secondarily the systemic immune-inflammation index (SII), monocyte-to-lymphocyte ratio (MLR) and platelet-lymphocyte ratio (PLR). Methods: A cross-sectional study. Results: Of the 82 patients who met the inclusion criteria, 59 patients had SA and observed a significant alteration in inflammation markers in patients with SZ, especially NLR.